Literature DB >> 20660112

Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease.

Jinho Kim1, Jennifer P Moody, Christina K Edgerly, Olivia L Bordiuk, Kerry Cormier, Karen Smith, M Flint Beal, Robert J Ferrante.   

Abstract

Although a direct causative pathway from the gene mutation to the selective neostriatal neurodegeneration remains unclear in Huntington's disease (HD), one putative pathological mechanism reported to play a prominent role in the pathogenesis of this neurological disorder is mitochondrial dysfunction. We examined mitochondria in preferentially vulnerable striatal calbindin-positive neurons in moderate-to-severe grade HD patients, using antisera against mitochondrial markers of COX2, SOD2 and cytochrome c. Combined calbindin and mitochondrial marker immunofluorescence showed a significant and progressive grade-dependent reduction in the number of mitochondria in spiny striatal neurons, with marked alteration in size. Consistent with mitochondrial loss, there was a reduction in COX2 protein levels using western analysis that corresponded with disease severity. In addition, both mitochondrial transcription factor A, a regulator of mtDNA, and peroxisome proliferator-activated receptor-co-activator gamma-1 alpha, a key transcriptional regulator of energy metabolism and mitochondrial biogenesis, were also significantly reduced with increasing disease severity. Abnormalities in mitochondrial dynamics were observed, showing a significant increase in the fission protein Drp1 and a reduction in the expression of the fusion protein mitofusin 1. Lastly, mitochondrial PCR array profiling in HD caudate nucleus specimens showed increased mRNA expression of proteins involved in mitochondrial localization, membrane translocation and polarization and transport that paralleled mitochondrial derangement. These findings reveal that there are both mitochondrial loss and altered mitochondrial morphogenesis with increased mitochondrial fission and reduced fusion in HD. These findings provide further evidence that mitochondrial dysfunction plays a critical role in the pathogenesis of HD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660112      PMCID: PMC2947400          DOI: 10.1093/hmg/ddq306

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  92 in total

1.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.

Authors:  Anthone W Dunah; Hyunkyung Jeong; April Griffin; Yong-Man Kim; David G Standaert; Steven M Hersch; M Maral Mouradian; Anne B Young; Naoko Tanese; Dimitri Krainc
Journal:  Science       Date:  2002-05-02       Impact factor: 47.728

Review 3.  Mitochondrial dynamics and division in budding yeast.

Authors:  Janet M Shaw; Jodi Nunnari
Journal:  Trends Cell Biol       Date:  2002-04       Impact factor: 20.808

4.  Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production.

Authors:  P Guidetti; V Charles; E Y Chen; P H Reddy; J H Kordower; W O Whetsell; R Schwarcz; D A Tagle
Journal:  Exp Neurol       Date:  2001-06       Impact factor: 5.330

5.  Characterization of a human import component of the mitochondrial outer membrane, TOMM70A.

Authors:  Angela M Edmonson; Douglas K Mayfield; Virginie Vervoort; Barbara R DuPont; George Argyropoulos
Journal:  Cell Commun Adhes       Date:  2002 Jan-Feb

Review 6.  Uncoupling proteins: their roles in adaptive thermogenesis and substrate metabolism reconsidered.

Authors:  A G Dulloo; S Samec
Journal:  Br J Nutr       Date:  2001-08       Impact factor: 3.718

7.  Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates.

Authors:  Hirokazu Fukui; Carlos T Moraes
Journal:  Hum Mol Genet       Date:  2007-03-13       Impact factor: 6.150

8.  Cytochrome C and caspase-9 expression in Huntington's disease.

Authors:  Tamara Kiechle; Alpaslan Dedeoglu; James Kubilus; Neil W Kowall; M Flint Beal; Robert M Friedlander; Steven M Hersch; Robert J Ferrante
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

9.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

10.  Dnm1p GTPase-mediated mitochondrial fission is a multi-step process requiring the novel integral membrane component Fis1p.

Authors:  A D Mozdy; J M McCaffery; J M Shaw
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

View more
  129 in total

Review 1.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.

Authors:  Miriam A Hickey; Chunni Zhu; Vera Medvedeva; Nicholas R Franich; Michael S Levine; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2011-10-20       Impact factor: 4.314

3.  Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Authors:  J Jean Chen; David H Salat; H Diana Rosas
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

Review 4.  Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission.

Authors:  P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2014-03-28       Impact factor: 7.851

Review 5.  Huntington's Disease and Mitochondria.

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi
Journal:  Neurotox Res       Date:  2017-06-21       Impact factor: 3.911

Review 6.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 7.  Mitochondrial morphology-emerging role in bioenergetics.

Authors:  Chad A Galloway; Hakjoo Lee; Yisang Yoon
Journal:  Free Radic Biol Med       Date:  2012-09-29       Impact factor: 7.376

8.  Bax interacting factor-1 promotes survival and mitochondrial elongation in neurons.

Authors:  David B Wang; Takuma Uo; Chizuru Kinoshita; Bryce L Sopher; Rona J Lee; Sean P Murphy; Yoshito Kinoshita; Gwenn A Garden; Hong-Gang Wang; Richard S Morrison
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

Review 9.  Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2020-04-11       Impact factor: 5.330

10.  Oxygen consumption deficit in Huntington disease mouse brain under metabolic stress.

Authors:  Song Lou; Victoria C Lepak; Lynn E Eberly; Brian Roth; Weina Cui; Xiao-Hong Zhu; Gülin Öz; Janet M Dubinsky
Journal:  Hum Mol Genet       Date:  2016-05-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.